Company intelligence / Profile preview

Syntrillo

Grand Rapids, Michigan, USA

Ownership: Private
Development stage: Other

Overview

Syntrillo is a Grand Rapids-based biotechnology company focused on developing novel small molecule therapeutics for neurodegenerative diseases, particularly Alzheimer's disease. The company was founded by Dr. Mark Gurney, who previously led Tetra Discovery Partners to a successful acquisition by Shionogi. Syntrillo's research centers on modulating the Integrated Stress Response (ISR) by targeting the eIF2B complex to restore normal protein synthesis in diseased neurons. By addressing the cellular stress pathways that lead to neurodegeneration, the company aims to provide disease-modifying treatments for conditions like Alzheimer's and ALS.

Therapeutic areas: Neurology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Syntrillo.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntrillo.

Explore the full profile